Clinical trials: L-DOPA Group
Parkinson's Disease, L-dopa Induced Dyskinesia
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
- Trial name
- NCT00888004
- Testing
- AFQ056
- Where
- 5 sites in Germany
- Volunteers
- 28 people
- Sponsor
- Novartis
Oxytocin Group, L-DOPA Group
Oxytocin and Dopamine's Effect on Vicarious Optimism
To investigate the effect of intranasal Oxytocin and L-DOPA's effect on vicarious optimism.
- Conditions
- Oxytocin Group, L-DOPA Group, Placebo Group
- Trial name
- NCT03891095
- Testing
- Oxytocin, L-DOPA
- Where
- China
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Beijing Normal University
Sub-acute Back Pain
Effect of L-dopa In Subacute Back Pain Population
This study aims to determine if early treatment with Carbidopa/Levodopa and Naproxen in individuals with sub-acute back pain (SBP) is associated with changes in blocking transition to chronic back pain (CBP).
- Trial name
- NCT01951105
- Testing
- Naproxen, Carbidopa/Levodopa
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Northwestern University
Gastroparesis
A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying
Gastric emptying is the end-result of a complex and carefully regulated series of events which follow the ingestion of a meal, each of which is dependent on the other and subject to neurohormonal control.
- Trial name
- NCT01602549
- Testing
- GSK962040 (25 mg tablet)
- Where
- 11 sites in Australia, Germany and 2 more
- Volunteers
- 58 people
- Sponsor
- GlaxoSmithKline
Parkinson Disease
The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
The main objective of the study is to explore firstly, then further evaluate and confirm the efficacy between Pramipexole Sustained Release (SR) versus Pramipexole Immediate Release (IR) on nocturnal symptoms (as measured by the…
- Trial name
- NCT03521635
- Testing
- Pramipexole SR, Pramipexole IR
- Where
- 12 sites in China
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD
A Study to evaluate the add-on efficacy and safety of opicapone 50 mg or an extra dose of L-DOPA 100 mg for the treatment of wearing-off in patients with PD.
- Trial name
- NCT04821687
- Testing
- Ongentys 50mg, Madopar Tab. 125 or Perkin Tab. 25-100mg
- Where
- South Korea
- Volunteers
- 169 people
- Sponsor
- SK Chemicals Co., Ltd.
Parkinson's Disease, Parkinson Disease
Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's
This study evaluates how effective a new formulation of a marketed drug is in increasing the time to onset of dyskinesia (abnormal twisting, writhing movements) in patients with Parkinson's Disease who have been taking levodopa…
- Conditions
- Parkinson's Disease, Parkinson Disease, Dyskinesias
- Trial name
- NCT00363727
- Testing
- ropinirole controlled-release (REQUIP CR) for RLS
- Where
- 69 sites in United States
- Volunteers
- 209 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa
This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.
- Trial name
- NCT00582673
- Testing
- AFQ056
- Where
- 5 sites in Germany
- Volunteers
- 31 people
- Sponsor
- Novartis
Parkinson Disease
Pivotal Study in Advanced Parkinsons Disease Patients
The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined)…
- Trial name
- NCT00466167
- Testing
- Pramipexol Extended Release, Pramipexol Immediate Release
- Where
- 76 sites in Austria, Czechia and 12 more
- Volunteers
- 517 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Approximately twenty four (24) subjects will participate in this research trial. The research trial will be conducted in approximately twelve (12) medical centers in the following countries: Germany, France, South Africa, Austria…
- Trial name
- Safinamide-LID (NCT01113320)
- Testing
- Safinamide
- Where
- 11 sites in Austria, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson Disease
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa
This is a phase III, multicenter, randomized, double-blind, parallel group, placebo-controlled study to compare the efficacy of 6-months therapy of ropinirole Prolonged Release (PR) with that of placebo as adjunctive therapy to…
- Trial name
- NCT01154166
- Testing
- ReQuip PR
- Where
- 18 sites in China
- Volunteers
- 347 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease
This study is a multicenter, randomized, double-blind, placebo controlled, parallel group study of a seven-week ascending dose period of SLV308 adjunctive to L-dopa treatment in patients with advanced stage Parkinson's disease…
- Trial name
- NCT00134251
- Testing
- SLV308
- Where
- 10 sites in Bulgaria, Malta and 1 more
- Sponsor
- Solvay Pharmaceuticals
Parkinson Disease
A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's
This study was designed to compare the effectiveness and tolerability of a new prolonged release formulation of ropinirole with the currently marketed immediate release formulation which is prescribed in many countries.
- Trial name
- NCT00331149
- Testing
- Ropinirole prolonged release, ropinirole immediate release
- Where
- 81 sites in Bulgaria, Canada and 12 more
- Volunteers
- 343 people
- Sponsor
- GlaxoSmithKline
Parkinson's Disease
A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients
To demonstrate the non-inferiority of SPM 962 to ropinirole in terms of efficacy in order to confirm clinical value of SPM 962. To demonstrate the superiority of SPM 962 to placebo in terms of efficacy.
- Trial name
- NCT01628926
- Testing
- SPM 962, Ropinirole
- Where
- 8 sites in Japan
- Volunteers
- 420 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinson Disease
A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period
The objective of this trial is to investigate the safety, tolerability, trough plasma concentration, and efficacy of pramipexole ER in comparison with those of pramipexole IR administrated orally for 12 weeks in patients with PD…
- Trial name
- NCT00560508
- Testing
- Pramipexole Immediate Release, Pramipexole Extended Release
- Where
- 19 sites in Japan
- Volunteers
- 112 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa
The purpose of this double-blind, placebo controlled study is to evaluate the safety and effectiveness of an investigational Parkinson's disease drug in patients with advanced disease who are not well-controlled on their L-dopa…
- Trial name
- NCT00381472
- Testing
- Ropinirole
- Where
- 76 sites in United States, Belgium and 7 more
- Volunteers
- 393 people
- Sponsor
- GlaxoSmithKline
Parkinson
Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)
Opicapone (OPC) is a third generation catechol O methyltransferase (COMT) inhibitor (COMTi) developed by BIAL-Portela \& Cª, S.A.
- Trial name
- EPSILON (NCT04978597)
- Testing
- Opicapone 50 mg
- Where
- Bulgaria
- Volunteers
- 410 people
- Sponsor
- Bial - Portela C S.A.
Dyskinesias, Drug-induced
Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease
This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.
- Trial name
- NCT01474421
- Testing
- AQW051
- Where
- 24 sites in United States, France and 2 more
- Volunteers
- 71 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease, Dyskinesia
Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia
The primary purpose of the study is to investigate the anti-dyskinetic effect of several doses of sarizotan in Parkinson patients in order to generate information on the dose-response relationship (dose-finding).
- Trial name
- NCT00314288
- Testing
- Sarizotan HCl
- Where
- 51 sites in United States, Belgium and 9 more
- Volunteers
- 360 people
- Sponsor
- EMD Serono